key: cord-0877379-hwfg4g6g authors: Rashid, M.; Wu, J.; Timmis, A.; Curzen, N.; Zaman, A.; Clarke, S.; Nolan, J.; Shoiab, A.; Mohamed, M. O.; De Belder, M.; Deanfield, J.; Gale, C.; Mamas, M. title: Clinical Characteristics and Outcomes of COVID-19 Positive Acute Coronary Syndrome Patients; a multisource Electronic Healthcare Records Study from England date: 2020-08-22 journal: nan DOI: 10.1101/2020.08.20.20175091 sha: 49d792b0923bc49c7fdb713bbe16adb547cc7762 doc_id: 877379 cord_uid: hwfg4g6g Background: Patients with underlying cardiovascular disease and Coronavirus disease 2019 (COVID-19) infection are at increased risk of morbidity and mortality. However, there is limited information on management and outcomes of patients presenting with acute coronary syndrome (ACS) and concomitant COVID19 infection. Objectives: This multisource national analysis of live data from England was designed to characterise the presenting profile and outcomes of patients hospitalized with ACS and COVID-19 infection. Methods: Multisource data from all acute NHS hospital in England was linked to study the characteristics and outcomes of patients hospitalized with COVID-19 ACS compared to non COVID-19 ACS patients. Hierarchical multilevel models were constructed to study the association between COVID19 ACS and in-hospital and 30-day mortality. Results: Between 1st March 2020 and 31st May 2020, 517 (4.0%) were admitted with COVID- 19 ACS from a total of 12,958 ACS patients. COVID-19 ACS patients were generally older, BAME ethnicity, more comorbid and had unfavourable presenting characteristics compared to non-COVID-19 ACS patients. They were less likely to receive invasive coronary strategy in the form of coronary angiography (67.7% vs 81.0%), PCI (30.2% vs 53.9%), dual antiplatelet medication 76.3% vs 88.0%), and other important secondary medication. Patients with COVID-19 ACS had higher in-hospital (aOR 3.27 95%CI 2.41-4.42) and 30-day mortality (aOR 6.53 95%CI 5.1-8.36) compared to non COVID-19 ACS group. Conclusion: COVID-19 infection is prevalent but less frequent in the patients hospitalized with ACS in England. Presence of COVID-19 infection in patients with ACS is associated with significant mortality hazard. Coronavirus disease 2019 , caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has affected more than 17 million people resulting in almost 700,000 deaths worldwide 1 survival of these patients 8, 9 . These reports lacked data around clinical presentation, pharmacological treatments and post-discharge survival. Fewer data are available from a national, or from a broader ACS perspective including non-ST-elevation myocardial infraction (NSTEMI). Such information could prove useful in order to devise optimal pathways of care in the event of a second wave of COVID-19. This study, using high resolution, multisource contemporary national data from England, systematically profiles the presenting and procedural characteristics, in-hospital and 30-day mortality in patients admitted with a suspected diagnosis of ACS and concomitant infection. The primary aim was to investigate the in-hospital and 30-day all-cause mortality in patients hospitalized with COVID-19 ACS diagnosis compared with those without COVID-19 ACS. The second aim was to describe the differences in management and independent predictors of 30-day mortality of those with COVID-19 ACS. An unselected, real-world cohort of all patients hospitalized with a suspected diagnosis of ACS in England was derived by linking patient records across four different sources of data, namely Hospital Episode Statistics (HES), the Myocardial Ischaemia National Audit Project (MINAP), the British Cardiovascular Intervention Society (BCIS) percutaneous coronary intervention registry and Civil Registration Death data. The full details about the validity, strengths, limitations and utility for research purposes have been described previously 10-12 . Briefly, HES contains International Statistical Classification of Disease-10 th Revision (ICD-10) clinical, geographic, administrative and patient information of all patients hospitalized in any National Health Service (NHS) hospital in England 10 . MINAP is an exclusive ACS registry designed to collect information across 130 data fields about patient demographics, use of various pharmacological and invasive treatments and in-hospital care of patients hospitalized with a suspected diagnosis of ACS (type 1 myocardial infarction) in any NHS acute care hospital in England 12 . Similarly, almost over 98% of the PCI activity in England is captured in the BCIS PCI registry, which is designed to collect detailed procedural and clinical data of all patients undergoing PCI 11 . Finally, the civil registration of death register holds the mortality information of all deaths in England. All patient records in these datasets can be identified using a unique 10-digit number. For the purposes of this study we used live reporting data from all hospitals in England submitting their data to these respective registries during the COVID-19 pandemic. This study was conducted under the endorsement of the Chief Scientific Advisor to the UK government and Scientific Advisory Group for Emergencies (SAGE and 'U072' (suspected) and linked with the MINAP record of the same patient matching across the two datasets based on their unique NHS number and admission date. In the second step, the records of all these patients were linked across to the records in the BCIS PCI registry using the same NHS number and admission week. Finally, the mortality information All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 22, 2020. Baseline characteristics were reported as number and percentages for categorical variables, means with standard deviation or median with interquartile ranges for continuous data. Statistical differences between the two groups were obtained using Chi-Square test or t-test or Table 1 ). Linear regression for continuous variables, multinomial for nominal variables, ordinal logistic regression for ordered factors and logistic regression models for binary variables were used to generate 10 imputed datasets and all subsequent analyses were performed on these and results were pooled using Robin's rule 17, 18 . To study the association between 'COVID-19 ACS' status and clinical outcomes, hierarchical logistic regression models with random intercept were constructed. The hospital ID was used as a random intercept to account for nesting of patients within the different hospitals. All models were adjusted for age, sex, ethnicity, body mass index, presenting characteristic (blood pressure, heart rate, cardiac arrest, clinical syndrome, creatinine, Kilip class, left ventricular systolic function), cardiovascular comorbidities (previous PCI, previous CABG, previous AMI, previous cerebrovascular event, peripheral vascular disease, renal dysfunction, heart failure, hypercholesterolemia, angina, diabetes, smoking status, asthma or chronic obstructive airway disease and family history of coronary heart disease), in-hospital pharmacology (low molecular weight heparin, unfractionated heparin, warfarin, loop diuretic, glycoprotein IIb/IIIa inhibitor), discharge pharmacology (dual antiplatelet medication use, statin, angiotensin converting enzyme (ACE) or angiotensin receptor blocker use), receipt of coronary angiography or PCI and cardiology care. For patients undergoing PCI, the association between 'COVID-19 ACS' status and mortality was estimated by constructing separate models adjusting all the procedural information reported in table 3 and in addition to the aforementioned confounders. The independent predictors of 30-day mortality were studied using multivariable logistic regression model. All tests were two-sided and statistical significance considered as P<0.05. Statistical analyses were performed in Stata MP 16.0 College station, Texas, US via secure remote access on the NHS Digital servers hosting all the datasets. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 22, 2020. . England, of which 517 (4.0%) were COVID-19 positive. There was a steady increase in the number of daily COVID-19 ACS hospitalizations during March, reaching a peak in the first week of April followed by a steady decline by the end of May ( Figure 1 ). Higher proportions of daily COVID-19 ACS cases were admitted with a suspected NSTEMI compared to STEMI throughout the study period. Patients in the COVID-19 ACS group were older compared with the non COVID-19 ACS group (72.8 year vs 67.0 year), and a greater proportion were from Black, Asian and Ethnic minority origin (20.2% vs 12.8%), they had a lower body mass index (26.9 vs 28.2) and more likely to be hospitalized with NSTEMI (67.0% vs 62.0%). The COVID-19 ACS group also exhibited an increased incidence of in-hospital cardiac arrest (6.3% vs 3.0%), higher troponin levels, and were more likely to have presented in pulmonary oedema (9.0% vs 3.4%) or cardiogenic shock (9.6% vs 3.9%). They had a higher prevalence of heart failure (23.7% vs 13.4%), cerebrovascular disease (15.7% vs 8.0%), insulin treated diabetes (13.6% vs 7.5%) and hypertension (69.4% vs 58.3%). Out of 12,958 patients, 6,864 (53.0%) underwent PCI and were successfully linked from MINAP into the BCIS registry (supplementary figure 1). COVID-19 ACS patients undergoing PCI were of similar age and had similar baseline characteristics to the overall ACS cohort ( Table 2 ). The angiographic and procedural profiles of COVID-19 ACS patients (such as number of lesions attempted, vessels attempted, multivessel PCI, number of stents used, use of intracoronary imaging such as IVUS, OCT and pressure wire use) were similar to the non COVID-19 ACS cohort undergoing PCI. From the patients who didn't receive All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted PCI, the proportions of angiographically normal coronaries or surgical disease were similar in both non COVID-19 and COVID-19 ACS groups. Patients in the COVID-19 ACS group were less likely to receive optimal secondary prevention medication such as aspirin (90.5% vs 94.5%), dual anti-platelet medications In the MINAP cohort, the COVID-19 ACS group had higher in-hospital (24.2% vs 5.1%) and 30-day mortality rates (41.9% vs 7.2%) compared with the non COVID-19 ACS cohort. After adjustment for baseline differences in demographics, presenting characteristics, comorbidities and pharmacology, the hierarchical multi-level logistic regression model showed a significantly higher risk of in-hospital (adjusted odds ratio 3.27 95%CI 2.41-4.42) and 30-day mortality (adjusted odd ratio 6.53 95%CI 5.12-8.36) in the COVID-19 ACS patients All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 22, 2020. . https://doi.org/10.1101/2020.08.20.20175091 doi: medRxiv preprint compared with non COVID-19 ACS patients ( Figure 2 ). In the subgroup analysis stratified according to type of ACS, although short term mortality was similar between the NSTEMI and STEMI groups, the NSTEMI group had higher mortality rates (adjusted odds ratio 8.45 95%CI 6.03-11.83) at 30-days. Similar, higher mortality rates were observed in COVID-19 ACS patients undergoing PCI compared with non COVID-19 ACS patients undergoing PCI. The multilevel regression model showed that increasing age per year, severe LVSD, inhospital cardiac arrest, peak troponin concentration levels, renal dysfunction and use of ACE/ARB on discharge were strong independent risk factors for 30-day mortality in the COVID-19 ACS group (Figure 3 ). This multisource, national report of contemporary data from all ACS related hospitalizations in England during the COVID-19 period provides detailed information about the risk profile, clinical care and outcomes of ACS patients with COVID-19 infection. Specifically, COVID-19 ACS group had over 6-fold increase in mortality within 30 days compared with non COVID-19 ACS and were less frequently prescribed appropriate secondary prevention medications. They were older, more likely to be of BAME origin, had more comorbid features and exhibited high risk presenting characteristics such as higher Killip class, troponin concentrations, creatinine and evidence of LV systolic dysfunction. A significant knowledge gap exists in the literature about incidence and profile of ACS patients with concomitant COVID-19 diagnosis, and their associated clinical outcomes. We report that COVID-19 infection in patients presenting with ACS is prevalent at a low level in a national cohort of patients. The higher prevalence of pulmonary oedema and shock at presentation, together with the higher troponin concentrations levels in the COVID-19 ACS cohort are suggestive of increased myocardial injury in this group corroborating findings All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 22, 2020. . https://doi.org/10.1101/2020.08.20.20175091 doi: medRxiv preprint from China and US cohorts 19, 20 . However, contrary to earlier small case series from New York and Italy 8, 9, 21 22 . In contrast, the North America and Canadian guidelines recommended use of thrombolysis as an alternative to primary PCI for patients with STEMI particularly where PCI services are restricted due to COVID-19 23, 25 . However, a joint statement from British Cardiovascular Society, BCIS and NHS England in the UK recommended that primary PCI should remain the default treatment for all STEMI, except in unusual circumstances 26 . In keeping with this national recommendation, we observed almost negligible use of thrombolysis for STEMI in the UK during the acute phase of the COVID-19 pandemic. By contrast, there were significant differences in the care of COVID-19 ACS patients in that only a third of COVID-19 ACS patients received PCI, they experienced greater delays in reperfusion treatment or an invasive strategy and had a significantly lower uptake of secondary prevention medications on discharge. Given that COVID-19 ACS patients presented with more complex, high risk features, there is an urgent need to develop All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 22, 2020. . https://doi.org/10.1101/2020.08.20.20175091 doi: medRxiv preprint effective treatment pathways to align their care with guideline recommendations 27, 28 . For patients hospitalized with suspected ACS, especially with elevated cardiac troponin minor ECG changes, an immediate COVID-19 testing should be advocated in the current climate. In the outcomes analysis, COVID-19 ACS patients had a poor prognosis compared with the non COVID-19 ACS patients. One of four patients died in hospital with an over sixfold higher 30-day mortality in the overall cohort as well as those undergoing PCI. Although we didn't have information regarding the presenting COVID-19 symptoms or respiratory complications in this cohort, we noted significantly higher levels of peak troponin, creatinine, a lower presenting blood pressure and tachycardia in this cohort. Troponin elevation three times the upper reference limit is known to be associated with worse in-hospital outcomes in COVID-19 patients 19, 20 . It remains unclear whether the rise in cardiac biomarkers is related to viral myocarditis 5, 6 or plaque rupture secondary to virus-induced inflammatory response [29] [30] [31] or a type 1 AMI. In this cohort of suspected type 1 myocardial infarction, there was a low prevalence of non-obstructive coronary disease and the angiographic characteristics and procedural management of the COVID-19 ACS were similar to the non COVID-19 ACS group. We observed higher rates of COVID19 infection and subsequent 30-day morality in NSTEMI compared with STEMI. Patients presenting with NSTEMI are generally older, more comorbid and less likely to present early during the COVID-19 pandemic which in conjunction with increased infection rates may be responsible for their poor outcomes. The COVID-19 ACS cohort were also less frequently prescribed low molecular weight or unfractionated heparin and statins. Patients with acute COVID-19 are known to be at increased risk of thromboembolic complications and are therefore likely to benefit from appropriate anticoagulation to reduce thrombus burden and statins to stabilize plaque. In the risk factor analysis, elevated creatinine, peak troponin, heart rate, left ventricular systolic dysfunction and use of ACE inhibitor or ARBs were strong independent risk factors for 30-All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 22, 2020. . https://doi.org/10.1101/2020.08.20.20175091 doi: medRxiv preprint day mortality in this report. Although recent data have negated earlier concerns of an increased risk of adverse outcomes in COVID-19 patients with use of ACE inhibitors or ARBs, further research is required to establish the role of these medications in patients presenting with COVID-19 ACS 32, 33 . Patients hospitalized with ACS and concomitant COVID-19 infection may also be focus of specific anti-viral drug trials or immunosuppression therapy to establish the benefit of these therapies in this high risk cohort 7 . The interrogation of multisource, multihospital live data from England has given insight in to the presenting characteristics, risk profile, treatment strategies and 30-day mortality in an unselected cohort of patients hospitalized with COVID-19 ACS. However, there are some study limitations which must be kept in mind whilst interpreting these findings. First, the COVID-19 diagnosis was based on the ICD-10 codes and so it is unclear whether the diagnosis at the hospital was made on clinical grounds or using a formal polymerase chain reaction (PCR) test, and the timing of the tests leading to the diagnosis is unclear. Moreover, other suspected ACS patients were not routinely tested at the start of the pandemic and we cannot say how many might have been carrying the virus, although the lack of a COVID-19 code suggests they did not have a clinical syndrome related to the virus. Second, information around COVID-19 symptoms, their duration and other organ involvement is not captured in the datasets used in this analysis, and hence it difficult to ascertain whether patients had COVID-19 symptoms followed by an ACS or vice versa, and whether COVID-19 infection occurred in the hospital or the community. Third, whilst the MINAP registry is the UK national ACS registry for suspected type1 AMI, we cannot rule out misclassification bias from misdiagnosis of myocarditis or type 2 AMI, although only a small proportion of cases that underwent angiography had non-obstructive coronary artery disease. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 22, 2020. . https://doi.org/10.1101/2020.08.20.20175091 doi: medRxiv preprint England during the study period. It was associated with worst outcomes independent of the type of ACS, however higher 30-day mortality was observed in NSTEMI group compared with STEMI group. Elderly, comorbid and BAME patients with underlying cardiovascular disease are more likely to acquire COVID-19 infection and often present with unfavourable presenting characteristics. These findings highlight the need to develop strategies for an efficient and equitable care for COVID ACS patients. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. <0.001 Table 3 : Angiographic characteristics and procedural outcomes of COVID19 ACS patients compared to non COVID19 ACS patients undergoing PCI in the BCIS registry All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted 1 41 (0.9%) 0 (0.0%) 2 175 (3.8%) 6 (6.0%) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted <0.001 Figure 1 : Daily cases of COVID19 ACS hospitalized during the study period All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 22, 2020. . https://doi.org/10.1101/2020.08.20.20175091 doi: medRxiv preprint Figure 2 : In hospital outcomes and 30-day mortality of COVID19 ACS patient compared to non COVID19 ACS patients Coronavirus COVID-19 Global Cases by the A Comprehensive Review of Manifestations of Novel Coronaviruses in the Context of Deadly COVID-19 Global Pandemic Extrapulmonary manifestations of COVID-19 Myocardial and Microvascular Injury Due to Coronavirus Disease First case of COVID-19 complicated with fulminant myocarditis: a case report and insights Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19) Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity ST-Segment Elevation in Patients with Covid-19 -A Case Series ST-Elevation Myocardial Infarction in Patients With COVID-19: Clinical and Angiographic Outcomes Hospital episode statistics: time for clinicians to get involved? British Cardiovascular Intervention Society registry framework: a quality improvement initiative on behalf of the National Institute of Cardiovascular Outcomes Research (NICOR) The Myocardial Ischaemia National Audit Project (MINAP) Mortality after percutaneous coronary revascularization: Prior cardiovascular risk factor control and improved outcomes in patients with diabetes mellitus Same-day discharge after elective percutaneous coronary intervention: insights from the British Cardiovascular Intervention Society No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Baseline risk, timing of invasive strategy and guideline compliance in NSTEMI: Nationwide analysis from MINAP Association Between Hospital Cardiac Catheter Laboratory Status, Use of an Invasive Strategy, and Outcomes After NSTEMI Multiple Imputation for Nonresponse in Surveys Multiple imputation after 18 years Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection Characteristics and Outcomes in Patients Presenting With COVID-19 and ST-Segment Elevation Myocardial Infarction CSC Expert Consensus on Principles of Clinical Management of Patients With Severe Emergent Cardiovascular Diseases During the COVID-All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder Precautions and Procedures for Coronary and Structural Cardiac Interventions During the COVID-19 Pandemic: Guidance from Canadian Association of Interventional Cardiology Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From the ACC's Interventional Council and SCAI Management of acute myocardial infarction during the COVID-19 pandemic Clinical guide for the management of cardiology patients during the coronavirus pandemic ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC) AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Covid-19 and cardiovascular risk: Susceptibility to infection to SARS-CoV-2, severity and prognosis of Covid-19 and blockade of the renin-angiotensinaldosterone system. An evidence-based viewpoint COVID-19-driven endothelial damage: complement, HIF-1, and ABL2 are potential pathways of damage and targets for cure Cardiac Manifestations of Coronavirus Disease 2019 (COVID-19): A Comprehensive Review Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19 Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19 No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted The authors acknowledge Chris Roebuck, Tom Denwood, Tony Burton and CourtneyStephenson and data support staff at NHS Digital for providing and creating the secure environment for data hosting and for analytical support, and Anil Gunesh and Julian Hains